V
Vinod Pullarkat
Researcher at City of Hope National Medical Center
Publications - 280
Citations - 9132
Vinod Pullarkat is an academic researcher from City of Hope National Medical Center. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 37, co-authored 219 publications receiving 6536 citations. Previous affiliations of Vinod Pullarkat include University of Southern California & Biogen Idec.
Papers
More filters
Journal ArticleDOI
Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy
Daniel A. Pollyea,Keith W. Pratz,Brian A. Jonas,Anthony Letai,Vinod Pullarkat,Andrew H. Wei,Marina Konopleva,Christian Recher,Olga Frankfurt,David A. Rizzieri,Tu Xu,Monique Dail,Brenda Chyla,Jalaja Potluri,Courtney D. DiNardo +14 more
TL;DR: This is an open-label, phase 1b, dose escalation and expansion trial studying the safety and efficacy of venetoclax in combination with decitabine or azacitidine in patients ineligible for intensive chemotherapy due to comorbidities and age.
Journal ArticleDOI
Erythropoietin-mediated expression of placenta growth factor is regulated via activation of hypoxia-inducible factor-1α and post-transcriptionally by miR-214 in sickle cell disease.
Caryn S. Gonsalves,Chen Li,Marthe-Sandrine Eiymo Mwa Mpollo,Vinod Pullarkat,Punam Malik,Stanley M. Tahara,Vijay K. Kalra +6 more
TL;DR: It is shown that treatment of human erythroid cells and colony forming units with erythropoietin (EPO) increased PlGF expression and that miR-214 expression could be induced by fenofibrate, a Food and Drug Administration (FDA) approved PPARα agonist, thus revealing a potential therapeutic approach for reduction in PlGF levels by increasing mi R-214 transcription.
Journal ArticleDOI
Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis
David S. Snyder,Joycelynne Palmer,Karl Gaal,Anthony S. Stein,Vinod Pullarkat,Firoozeh Sahebi,N. Vora,Ryotaro Nakamura,Stephen J. Forman +8 more
TL;DR: The combination of tacrolimus/sirolimus +/- methotrexate (MTX) for GVHD prophylaxis in the setting of RIC HCT for MF appears to reduce the incidence of severe aGVHD and NRM, and leads to improved OS compared to CSA/MMF+/-MTX.
Journal ArticleDOI
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Patrick W. Burke,Ibrahim Aldoss,Matthew A. Lunning,Sean M. Devlin,Martin S. Tallman,Vinod Pullarkat,Ann M. Mohrbacher,Dan Douer +7 more
TL;DR: Pegaspargase at this dose and interval is associated with high hepatotoxicity rates, but patients can be rechallenged despite earlier pegasp argase-related hepatot toxicity.
Journal ArticleDOI
Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors
TL;DR: It is concluded that exposure to DFX results in dose-dependent inhibition of proliferation, and survival in MDS progenitors.